Texas Researchers Find New Path to Treat Rett Syndrome

A team at Texas Children's Hospital just opened a door that thousands of families have been hoping to find.

Researchers discovered a potential treatment for Rett syndrome, a devastating genetic disorder that steals abilities from young girls after their first year of life. The condition, which affects about 1 in 10,000 girls, causes severe problems with movement, speech, and communication.

Dr. Huda Zoghbi and graduate student Harini Tirumala led the team that published their findings in Science Translational Medicine. They focused on a protein called MeCP2, which is essential for normal brain function but doesn't work properly in Rett syndrome patients.

Here's where it gets exciting. The brain naturally makes two versions of the MeCP2 protein, called E1 and E2. The researchers realized that E2 isn't necessary for brain function and has never been linked to causing Rett syndrome.

The team had a clever idea: what if they could convince the brain to make more of the helpful E1 version by skipping E2 production entirely? They tested this in mice by removing the genetic instructions for E2.

The results were remarkable. MeCP2 protein levels jumped by 50% to 60% in normal mice. When they tried the same approach in cells from Rett syndrome patients, the cells recovered their normal structure and electrical activity.

The researchers then tested synthetic molecules called morpholinos that block E2 production. These molecules successfully increased MeCP2 protein levels in mice, proving the concept could work as a treatment approach.

Why This Inspires

This discovery matters because about 65% of Rett syndrome patients have partially working MeCP2 protein that just needs a boost. Previous research showed that increasing even slightly functional protein levels improved symptoms in mice, including survival, movement, and breathing.

The challenge with treating Rett syndrome has always been balance. Too little MeCP2 causes Rett syndrome, but too much causes a different neurological disorder. This new approach elegantly sidesteps that problem by working within the body's natural system.

While morpholinos themselves aren't safe enough for human use, similar therapies called antisense oligonucleotides are already treating other conditions successfully. The research team believes these safer alternatives could be adapted for Rett syndrome.

For families watching their daughters lose abilities they once had, this research offers something precious: a scientifically solid path forward where none existed before.